InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Browse the full record of transactions filed by Johnson Brady, Chairman & CEO. Officer active across 1 company, notably Cidara Therapeutics, Inc.. In total, 9 reports have been published. Breakdown: 0 buy · 2 sells. Total volume traded: €1k. History available since 30 September 2021. The latest transaction was disclosed on 31 March 2022 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations9 total
10,000 shares0Common StockSEC:0001610618-22-000031:0
654 shares@ US$0.8144.1% of flowCommon StockSEC:0001610618-22-000015:0
945 shares@ US$0.7155.9% of flowCommon StockSEC:0001610618-22-000013:0
262 shares0Common StockSEC:0001209191-22-002602
262 shares0Common StockSEC:0001209191-22-002602:0
20,750 shares0Common StockSEC:0001610618-21-000097:0
20,750 shares0Common StockSEC:0001610618-21-000097
20,750 shares0Common StockSEC:0001610618-21-000095:0
20,750 shares0Common StockSEC:0001610618-21-000095
9 of 9 declarations
About Johnson Brady
Brady Johnson is the CEO of Cidara Therapeutics, Inc. He oversees the company's operations and is responsible for the overall strategy. With a strong background in the biopharmaceutical sector, Brady Johnson is committed to advancing Cidara Therapeutics, Inc.'s research and development initiatives to improve medical treatments.
